Trial Profile

A Phase I/II Study for Subretinal Injection of NGGT001 in Patients With Bietti Crystalline Corneoretinal Dystrophy

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NGGT 001 (Primary)
Indications Bietti crystalline dystrophy
Focus Adverse reactions; Therapeutic Use
Sponsors Next Generation Gene Therapeutics

Most Recent Events

25 May 2025 Planned primary completion date changed from 26 Mar 2025 to 30 Nov 2025.
14 Jan 2025 According to the Next Generation Gene Therapeutics Media Release, result from this study published in the journal JAMA Ophthalmology.
14 Jan 2025 Results presented in the Next Generation Gene Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com